• Inhibrx reported updated interim results from Phase 1/2 study of ozekibart (INBRX-109) with FOLFIRI in late-line metastatic colorectal cancer, with results already presented in an April 21, 2026 webcast.
• Trial showed meaningful tumor shrinkage with durable disease control in heavily pretreated patients, outperforming typical outcomes seen with existing options.
• Safety profile remained manageable, with side effects largely consistent with chemotherapy and no notable liver toxicity despite high baseline liver metastases.
• Inhibrx plans FDA talks in 2H 2026 to support a first-line registrational colorectal cancer trial.
• Company also plans to discuss accelerated regulatory pathways for fourth-line colorectal cancer, with a separate BLA submitted in April 2026 for conventional chondrosarcoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604211605PR_NEWS_USPR_____LA40034) on April 21, 2026, and is solely responsible for the information contained therein.